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Background. Studies have shown that asthma and asthma exacerbations are related to body weight and that this relationship
might be sex-specific. While oral corticosteroids have been associated with weight gain, little is known about the eﬀect of inhaled
corticosteroid (ICS) use on short-term weight gain. The purpose of the present study was to examine whether ICSs would be
associated with weight gain among asthmatic patients. Methods. A total of 180 adult patients with physician-diagnosed asthma
provided details of their medical history and demographic information, along with height and weight at baseline and at one year.
Weight change was defined as follow-up minus baseline weight. General linear models were used to assess the relationship between
ICS dose (fluticasone propionate equivalent) and sex. Results. Significant main eﬀects of sex (P = .005) and ICS dose (P = .036)
and an interaction eﬀect of sex and ICS dose (P = .003) on weight change were observed. Further analysis of the interaction
indicated that women had greater weight gain, while men had decreased weight with increased ICS dose. Conclusions. Findings
suggest that ICSs may trigger weight gain in females and highlight the need for studies to confirm this relationship and examine
the potential underlying mechanisms.
1. Introduction
One of the main physiological characteristics associated with
asthma is chronic airway inflammation, which is usually con-
trolled through the use of inhaled corticosteroids (ICSs) [1].
This medication is commonly prescribed as a preventative
treatment to reduce and manage the number of exacerba-
tions experienced by asthmatic patients [1]. With its intro-
duction in 1972, it was created with the intention of mini-
mizing adverse eﬀects normally associated with oral corticos-
teroids, including decreased bone mineral density, cataracts,
ecchymosis, skin atrophy, ocular hypertension, glaucoma,
and weight gain, by creating a direct pathway to the lungs
thereby decreasing systemic absorption [2]. Despite these
intentions, research has revealed that ICS’s bring about some
adverse systemic eﬀects while still remaining more systemi-
cally eﬃcient and safe compared to their oral counter-parts
[1, 3–5]. One adverse eﬀect of oral corticosteroids, which has
not been widely assessed with ICS’s in adults, is weight gain.
Worldwide, the prevalence of obesity has more than
doubled since 1980 [6]. In 2008, 1.5 billion adults, 20 years
of age and older, were overweight. Of these overweight
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individuals, over 200 million men and nearly 300 million
women were considered obese [6]. These increases have a
profound impact on the prevalence of a wide variety of
chronic diseases [7], including asthma. Numerous studies
have revealed an association between asthma and obesity [8–
12], though the mechanistic link between the two [13, 14]
and their temporal association remain hotly debated. As
such, it is important to examine whether ICS’s could possibly
be associated with weight gain in an asthmatic population. In
the present study, it was hypothesized that the use of ICS’s
would result in short-term (one-year) weight gain among
patients with asthma. A secondary goal was to investigate
the sex-specific nature of this relationship, as it has been
suggested that the link between asthma and obesity may
be more prevalent among women [11]. As such, it was
hypothesized that women with asthma would have a greater
weight gain at one year compared to men.
2. Methods
2.1. Study Participants. Patients in this prospective study
were recruited from the asthma outpatient clinic at l’Hoˆpital
du Sacre´-Coeur de Montre´al from June 2003 to Dec 2006. A
total of 801 patients were recruited at baseline, constituting
94% of all eligible patients. Of those patients, 180 (22.5%)
returned at one year for a clinically required followup and
were reassessed as part of the present substudy. Patients were
eligible to participate if they had physician-diagnosed asthma
(confirmed by spirometry and/or methacholine challenge),
were between the ages of 18 and 75 years, and were fluent
in English or French. Patients were ineligible to participate
if they had a comorbid disease which conferred greater
risk for morbidity than asthma (i.e., COPD, cardiovascular
disease, etc.), a primary diagnosis of occupational asthma,
the presence of severe psychopathology (e.g., schizophrenia),
dementia, substance abuse, or if they were pregnant. More
specifically, patients were confirmed as having asthma by
chart-documented bronchodilator reversibility in FEV1 ≥
20% predicted and/or a 20% fall in FEV1 after metacholine
challenge [15]. One person was excluded from the analyses
as they had a baseline body mass index (BMI) greater
than 50 kg/m2. This study was approved by the institutional
ethics research board and all participants provided written,
informed consent prior to participating in this study.
2.2. Study Design. This study was conducted as part of
a larger epidemiological study assessing psychosocial risk
factors for asthma morbidity (Psychosocial and Behavioural
Risk Factors for Asthma Longitudinal Study, PAL Study)
[16]. During the baseline visit, patients underwent a sociode-
mographic and medical/asthma history interview, during
which patient’s self-reported height and weight and all med-
ications were recorded. For patients taking ICS medication,
information regarding type of medication and dosage were
obtained. All clinical information and medications were
systematically verified through chart review. All participants
provided the same information at the one-year follow-up
visit.
2.3. Measures. Self-reported height and weight values were
obtained from the patients to calculate BMI (weight in
kg/height in m2). Weight status was classified as normal
for patients with a BMI less than 25 kg/m2, overweight for
patients with a BMI between 25 kg/m2 and 29.9 kg/m2, or
obese for those with a BMI equal to or exceeding 30 kg/m2.
With respect to ICS use, participants provided details about
the frequency and dose of ICS medication. All values were
converted to fluticasone propionate equivalents and reported
as dose per day. All patients underwent standard pulmonary
function testing using standard spirometry in the respiratory
laboratory by a trained respiratory technician on the day of
the patient’s visit. Rescue medication was withheld for at
least 4 hours (but up to 8) prior to testing. Predicted values
of FEV1 and FVC were calculated from reference values for
patients less than [17] and greater than [18] 70 years of age,
respectively, yielding percentage of the predicted FEV1 and
percentage of the predicted FEV1/FVC ratio.
2.4. Data Reduction and Analyses
2.4.1. Main Analyses. Weight change was defined as follow-
up weight minus baseline weight. General linear models
(GLMs) were used to assess the relationship between ICS
dose and sex, defined as our independent variables, and
weight change, defined as our dependent variable. Covariates
were defined a priori based on their potential influence on
the expected relationships under investigation and included
age, baseline smoking status, change in smoking status, level
of education, baseline weight, duration of asthma, use of oral
corticosteroids, and baseline FEV1. All patients with data at
1 year were included in the analyses. All statistical analyses
were performed using SAS v9.1 (SAS, Cary) and P < .05 was
considered statistically significant.
2.4.2. Missing Data. Our missing data analysis procedures
used missing at random (MAR) assumptions, as per Rubin’s
rules [19]. We used the PROC MI method of multiple
multivariate imputation in SAS. We independently analyzed
5 copies of the data, each with missing values suitably
imputed, in the GLM analyses. Using PROC MIANALYZE,
we averaged estimates of the variables to give a single mean
estimate and adjusted standard errors according to Harrell’s
guidelines [20]. Details of the amount of missing data per
variables are included in Table 1.
3. Results
Baseline sociodemographic, clinical, and asthma charac-
teristics are presented in Table 1. A total of 61% of the
participants were women and had a mean (SD) age of
51(14). The mean ± SD of ICS dose (fluticasone propionate
equivalent) was 776 ± 568μg for women and 716 ± 460μg
for men. Clinical/asthma characteristics are indicative of an
asthmatic population from a tertiary care setting; as such,
it is unsurprising that ICS doses were generally higher than
those found in asthmatic populations followed in primary
care [21].
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Table 1: Patient demographics.
Characteristics Women Men Percentage of missing information (n)
Sociodemographics
n# 109 71 0 (0)
Age, yr# 51.4 ± 13.5 48.3 ± 13.5 2 (4)
White race, % (n) 94 (100) 91 (64) 2 (4)
Education, yr# 12.9 ± 3.4 13.4 ± 3.7 4 (7)
Employed, % (n) 64 (66) 73 (51) 4 (7)
Cohabitating, % (n) 65 (67) 70 (49) 4 (7)
Weight, kg# 67.5 ± 15 87.2 ± 19.3 2 (4)
Baseline BMI, kg/m2 26 ± 5.4 28.1 ± 6.3 2 (4)
Pulmonary function
FEV1, % predicted# 78.0 ± 19.5 76.2 ± 21.5 7 (13)
FVC, % predicted# 88.0 ± 16.3 89.0 ± 20.2 8 (14)
FEV1/FVC, % predicted 72.6 ± 10.7 69.3 ± 10.1 8 (14)
Asthma history
Asthma control (ACQ level) 1.5 ± 1.1 1.4 ± 0.9 2 (4)
Atopic#, % (n) 69 (72) 70 (49) 3 (5)
Asthma medications
Short-acting β2-agonists#, % (n) 96 (102) 100 (70) 2 (4)
Long-acting β2-agonists#, % (n) 83 (88) 74 (52) 2 (4)
ICS#, % (n) 100 (106) 99 (69) 2 (4)
ICS dose∗#, μg 776 ± 568 716 ± 460 14 (25)
Oral corticosteroids#, % (n) 13 (14) 6 (4) 2 (4)
Antileukotrienes#, % (n) 15 (16) 10 (7) 2 (4)
Antirhinitics#, % (n) 25 (27) 14 (10) 2 (4)
Data are presented as mean ± SD or % (no.).
FEV: forced expiratory volume; FVC: forced vital capacity; ICS: inhaled corticosteroids.
∗Fluticasone propionate equivalent (μg).
#Used in the multiple imputation process.
The analyses revealed a significant main eﬀect of sex (β
(95% CI) = 4.099 (1.221–6.976), P = .005) and ICS dose
(β (95% CI) = .002 (.0001–.004), P = .036), as well as a
significant interaction eﬀect of sex and ICS dose (β (95%
CI) = −.005 (−.008–−.002), P = .003) on weight change.
The interaction eﬀect indicated that for women, increasing
ICS dose was associated with greater 1-year weight, while
for men, higher ICS dose at baseline predicted lower weight
change at 1 year (Figure 1). Based on separate regression
models for women and men, it would appear that for every
500 μg of fluticasone equivalent of ICS at baseline, men
would lose 1.30 kg (95% CI = −2.84–0.25) of weight at 1
year, whereas women would gain 0.94 kg (95% CI = 0–1.89)
of weight. For the combined cohort of women and men, a
gain of 1.07 kg (95% CI = .07–2.07) was observed.
To assess the potential causal pathways of this relation-
ship, an analysis of the impact of baseline body weight on
1 year ICS dose was conducted. This analysis revealed no
significantmain eﬀect of sex (β (95%CI) = 409.65 (−864.21–
869.15), P = .995), weight (β (95% CI) = 3.88 (−12.86–
3.62), P = .252), nor their interaction (β (95% CI) = 5.21
(−10.81–11.27), P = .965) on ICS dose change. For all
analyses, the same pattern of results was seen if baseline BMI
was used instead of weight.
4. Discussion
Findings from the current study showed that women taking
higher dosages of ICS’s experienced greater increases in
weight over the course of one year, with an average gain
of.94 kg (2.1 lbs) per year, while men tended to experience
a decrease in weight with an increase in ICS dose, with
an average loss of 1.3 kg (2.9 lbs) per year. Similar results
were obtained in a previous study conducted in asthmatic
children. Indeed, Jani et al. [22] found that asthmatic
children aged one to twelve years receiving ICS doses
above 400 μg/day had an annual increase of .44 kg/m2/year
(P = .0003) in BMI compared with those receiving less
than 200 μg/day, who showed an increase of .10 kg/m2/year
(P = .0003). These results were independent of the type
of ICS and inhaler device utilized [22]. This study did not,
however, explore sex diﬀerences [22]. To our knowledge,
no other study has investigated the association between ICS
dose and weight gain in an adult population. One study
conducted by Hedberg and Ro¨ssner did, however, investigate
if a relationship exists between body weight and asthma
medications in a Swedish population 16–60 years of age (n =
17,912). They found there to be no strong evidence to suggest
such a relationship in men or women [23].
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Figure 1: Relationship between change in weight (kg) and ICS dose
(μg fluticasone equivalent) in women (dashed line) and men (solid
line).
Several researchers have explored the obesity-asthma
phenomenon and identified this relationship as a sex-specific
one, where women with increased BMI’s are at greater risk
for asthma than women with lower BMIs [9, 12, 24, 25].
For example, a study conducted by Beckett et al. concluded
that weight gain disposes young females to new asthma
diagnoses, independent of physical activity [24]. However,
this relationship was not observed in young males. In a larger
study, Chen and colleagues [25] investigated the relationship
between asthma and energy expenditure and concluded that
obesity was related to the development of asthma in women
but not in men. Once again, physical inactivity measured by
energy expenditure did not explain this association [25].
An extensive body of literature suggests a strong corre-
lation between obesity and asthma [9–11, 24, 26]. Though
controversial, the current paradigm of directionality for this
relationship is that obesity increases the risk of developing
asthma [9–11, 24, 25]. There are a number of poten-
tial mechanisms that may help explain this directional
association [27]. These mechanisms include genetics [28],
obesity leading to histological changes within the lung [29],
decreased airway caliber as a result of chest restriction [30],
and sex hormones being influenced by obesity subsequently
increasing the risk of asthma [31, 32]. However, it has
also been indirectly proposed that asthma may lead to
obesity. For instance, oral corticosteroids have been shown
to bring about weight gain through systemic absorption
of this medication, thereby suppressing the hypothalamic-
pituitary-adrenal (HPA) axis, which in turn brings about
weight gain [33]. It is possible that such a pathway may
explain the current findings. It has been suggested that when
an ICS is taken, 10–40% of the medication reaches the
lung and 60–90% is swallowed [34]. This swallowed portion
gets absorbed by the gastrointestinal tract and then passes
through the liver leaving a fraction bioavailable to reach the
systemic circulation [34]. Once in the systemic circulation,
unwanted adverse eﬀects may be experienced; furthermore,
it has been reported that these eﬀects are dose-dependent
[34, 35]. Though we were not able to assess this in the current
study, it represents an important avenue for future research
and highlights the importance of using appropriate inhaler
techniques among asthmatics.
Given the diﬀerential weight gain in women compared to
men in the current study, it is possible that female hormones
may play a role in this relationship. The most compelling evi-
dence that female sex hormones play a role in asthma appears
in natural models (i.e., menstrual cycle, pregnancy, and
menopause) [14]. Sex diﬀerences can actually be observed
as early as gestation, where the lung of a female fetus
matures more rapidly than that of a male fetus [36]. During
childhood, the prevalence of asthma is higher in boys than in
girls; a relationship that is reversed once girls reach puberty,
a stage when estrogen levels are higher suggesting a possibly
etiological role [13, 37]. In addition, asthma symptoms have
been shown to subjectively worsen during menstruation [38,
39], although other studies have contradicted this finding
[40]. In addition, pregnancy is generally characterized by
changes in asthma symptoms, ranging from improvements
(i.e., reductions in airway hyperresponsiveness) to a wors-
ening of asthma symptoms [13]. A study conducted by
Troisi et al. [41] evaluated the association between hormone
replacement therapy (conjugated estrogens) and increased
asthma incidence. These investigators found that women
who were naturally menopausal and reported never using
postmenopausal hormones had a significantly lower risk of
incident asthma compared to premenopausal women [41].
Finally, estrogens could act in synergy with leptin, which
plays a central role in fat metabolism through the regulation
of energy intake and expenditure and is positively correlated
with body fat and BMI [42]. Leptin receptors exist in human
lung tissue [43] and plasma leptin levels have been observed
to be higher in women compared to men, independent of
obesity [44]. Cytokines, such as IL-6, IL-1β, and TNF-α,
are also involved in metabolism and food intake. TNF-α
and IL-1β both modulate the release of leptin, and TNF-
α and IL-6 act directly on the hypothalamus by altering
the regulation of food intake [45, 46]. These relationships
suggest that estrogen (both alone and via interactions with
leptin) may play a key role in the pathophysiology of asthma
and could perhaps help explain why sex diﬀerences were
observed in this study. Aside from sex hormones, the fact
that men tend to have more muscle mass than fat mass as
compared to women may have also contributed to the sex
diﬀerences observed in this study. In addition, the weight loss
experienced by men could have improved asthma control
thereby reducing the need for medication use [47].
Several behavioural factors may also help explain sex
diﬀerences in the relationship between ICS use and weight
gain. A study conducted by Sundberg and colleagues [48]
comparing sex diﬀerences among 470 asthmatic men and
women found that women had greater self-reported adher-
ence to ICS’s and tended to have a more positive attitude
towards their medication, relative to men. Furthermore,
women reported having a higher prevalence of insomnia
and day-time sleepiness compared to men, which has been
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proposed by some as a potential cause of weight gain
[48]. Future studies are needed to clarify sex diﬀerences in
behavioural factors associated with weight gain and ICS use
among asthmatic patients.
4.1. Study Limitations and Strengths. The results of this study
need to be interpreted in the context of some limitations.
The current study utilized self-report measures of height and
weight to calculate BMI. However, data from the National
Health and Nutrition Examination Survey (NHANES-III)
study suggests that the BMI values derived from self-reported
height and weight are highly correlated (r = .89 to .97,
P < .001) with measured height and weight values in both
men and women [49], particularly in individuals under the
age of 60, which is well within the average age (i.e., 50
years) of the present sample. A second limitation is that
this was a convenience sample, as we only have data on a
subset of patients who returned to the clinic for the one-
year followup. As a result, our sample population may be
somewhat biased in the sense that those who returned would
be expected to have the most severe or poorly controlled
asthma (as shown in Table 1 in their relatively higher ACQ
scores). An example of this is the fact that there was a
higher than usual number of people with a prescription
of oral corticosteroid (though this was still a relatively low
proportion, ca. 10%) and the use of such medications may
have had an impact on our main question. To account for
this we did adjust for oral corticosteroid use in our analyses.
Though this population may not be consistent with a family
physician seen population of asthmatics, it may be the most
relevant group to examine due to their poor control thereby
requiring higher ICS doses, thus making them at potentially
higher risk for weight gain. In addition, ICS adherence was
not measured in this study, which may have influenced the
overall weight changes observed in the present study, and
the relative weight gain observed in men versus women if
adherence diﬀered by sex. In general, asthma patients tend to
show poor adherence to ICS’s [50–52]. Given that we found
that increased prescribed doses of ICS’s were associated
with increased weight gain in women, if patients were less
adherent to their medications, this would suggest that our
results would, at worst, reflect an underestimation of the
eﬀects of ICS on body mass. In addition, a study by Ip et
al. [4] found that asthma patients (women in particular)
receiving long-term ICS’s had significant decreases in bone
mineral density, leading to decreases in body mass. If ICS’s
bring about weight gain, but also weight loss due to a
loss of bone mineral density in women, this could further
underestimate our results. Future studies need to assess not
only the relationship between the prescribed doses of ICS
medication, but also patient adherence to ICS’s, in order to
further elucidate potential causal mechanisms.
Another limitation of our study is that we were unable
to acquire data on diet or physical activity levels, which was
largely due to the desire to minimize patient assessment
burden. However, given the observational nature of this
study, it is unlikely that a significant enough change in these
complex health behaviours would have likely influenced our
results. We were also unable to assess hormonal status in
women which has been proposed as a potential mediating
factor in the BMI-asthma relationship [53]. Given that this
study focused on patients treated in tertiary care, this study
may not be generalizable to patients treated in primary care
or community samples. However, given that our sample
was comprised primarily of moderate-severe asthmatics who
tend to receive the highest doses of ICS’s, our focus on
tertiary care asthmatics may also be viewed as appropriate
and a strength, as weight gain may be relevant to this
subpopulation of asthmatics due to their needs for higher
doses of ICS’s. Finally, as we only assessed weight change
and not actual body fat, it is possible that the changes we
observed reflected increases in muscle mass and not increases
in adiposity. However, previous studies have shown that
yearly increases in body weight in middle-aged individuals
are generally driven by increases in fat mass rather than fat-
free mass [54]. Future studies are needed to assess if this is
also true of patients taking ICS’s.
Despite some limitations, this study also has a number
of important strengths. Such strengths include the use of
a prospective study design as well as a well-characterized
sample of moderate to severe asthmatics whose diagnoses
were objectively confirmed. We assessed sex diﬀerences and
included the statistical control of important covariates such
as smoking cessation in our main analyses. Additionally, we
used multiple imputation to deal with missing data, resulting
in a complete dataset for all participants. These novel and
perhaps provocative findings may stimulate future research
and further inform the asthma-obesity literature.
4.2. Clinical Relevance. The consequences of obesity are
serious as this condition has a profound impact onmorbidity
and mortality rates and is associated with other diseased
states [7]. Though mechanistic studies and replications are
needed, our results suggest that higher ICS doses bring
about weight gain in female patients with asthma. A study
conducted by Sun et al. [55] found that for every 1 unit
increase of BMI, there was a 12% reduction of the odds
of healthy survival. Additionally, they found that for every
1 kg increase in weight gain since the age of 18, the odds of
healthy survival in women decrease by 5% [55]. Given that
weight gain is a concern for many patients [56], particularly
women, intervening and providing help with weight control
and management may encourage more patients to adhere
to their medication regimen and improve asthma outcomes
[57]. Applying a preventative approach to weight gain can
be accomplished through referral to exercise specialists,
dieticians/nutritionists, or behavioural weight management
counsellors. Future studies are necessary to investigate if
such an intervention can alter the potential ICS-weight gain
relationship. Furthermore, given the finding that higher ICS
use inmenwas associated with weight loss, further research is
needed to explore the reasons for and potential clinical utility
of this finding.
5. Conclusion
In a sample of 180 asthmatic patients, higher ICS doses
were associated with an increase in body weight at one
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year in women and with a decreased weight in men. These
findings suggest a temporal association between asthma and
increased body weight among women and points to the
possible role of ICS medication use. Further research is
needed to clarify the extent to which this relationship is
influenced by sex hormones, dietary and exercise behaviours,




BMI: Body mass index
CI: Confidence interval.
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